Elisavet TheodoulouElisavet Theodoulou


I studied medicine at the University of Patras (Greece) where I graduated in 2009. I moved to the UK in 2011. I worked as a Junior Doctor in different hospitals in the UK. Since 2016, I have been working at Weston Park Hospital, in Sheffield as a Medical Oncology Specialist Registrar. In September 2018, I started my PhD under the supervision of Professor Ingunn Holen, Professor Janet Brown and Dr Caroline Wilson.

My PhD project is entitled “Menopausal status modifies breast cancer progression and response to treatment” and is funded by Yorkshire Cancer Research (https://yorkshirecancerresearch.org.uk/). This project has arisen directly from a major international clinical trial, conceived, developed and run from Sheffield. The AZURE trial showed that menopausal status is a significant modifier of the effects of zoledronic acid in early breast cancer. Whereas, postmenopausal women benefitted from adjuvant zoledronic acid, this was not seen in premenopausal women. The aim of this project is to identify the mechanisms responsible for this differential effect. We will run a clinical trial, ZOLMENO, in which 40 premenopausal and 40 postmenopausal women with early breast cancer will randomly assigned to received zoledronic acid either before breast cancer operation or after. We aim to identify the changes in reproductive hormones in these 2 group of patients, before and after surgical excision of the primary tumour. Also, our objective is to identify changes in bone and tumour microenvironment of these women.

I hope to find out the reason why adjuvant bisphosphonates benefit postmenopausal women but not premenopausal. I also intend to identify which group of early breast cancer patients benefit most from adjuvant bisphosphonates and suggest new treatment options for those who do not benefit.